Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Botox Dose Response in BPH
NCT02524236Phase 1Completed
- Sponsor
- Beni Suef University
- Start
- Aug 2015
- Primary completion
- Nov 2016
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of botulinum toxin type A in benign prostatic hyperplasia (BPH), sponsored by Beni Suef University. Primary endpoint: International Prostatic Symptom Score improvement at 3 months. Started Aug 2015; status: completed.
02
Drugs
botulinum toxin type A
03
Conditions
benign prostatic hyperplasia (BPH)
Beyond the preview
Go deeper on NCT02524236.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02524236.